

CERUS CORP  
Form 8-K  
September 04, 2003

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 4, 2003**

## CERUS CORPORATION

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of jurisdiction)

**0-21937**  
(Commission File No.)

**68-0262011**  
(IRS Employer Identification  
No.)

**2411 Stanwell Drive**  
**Concord, California 94520**  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(925) 288-6000**

**Item 5. Other Events.**

On September 4, 2003, Cerus Corporation (the Company) and subsidiaries of Baxter International Inc. announced they are voluntarily halting Phase III trials for their pathogen-inactivated red blood cell program. A copy of the Company's press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 7. Exhibits.**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release, dated September 4, 2003, entitled Baxter and Cerus halt red blood cell clinical trials for investigational pathogen inactivation system.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CERUS CORPORATION**

Dated: September 4, 2003

By: /s/ Gregory W. Schafer  
Gregory W. Schafer  
Vice President, Finance and  
Chief Financial Officer

**Index to Exhibits**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release, dated September 4, 2003, entitled Baxter and Cerus halt red blood cell clinical trials for investigational pathogen inactivation system.